Phytopharm

www.phytopharm.co.uk

Symbol: PYM.L

Currently trading at: 9.32p UP 0.07

Phytopharm is focused on the research and development of novel pharmaceutical and functional food products based on clinical and pre-clinical data generated from medicinal plant extracts.

The Company has seven development programmes in four disease areas: neurodegeneration, obesity and metabolic disease, dermatology and inflammation and has a portfolio of two marketed veterinary products.

It is listed in the LSE

Staff

Contact details

Articles relating to Phytopharm

Just five Silicon Fen high techs hold back the stock market red ink

Listed Silicon Fenners show cause for celebration, and concern

New CEO for Phytopharm

Phytopharm, Unilever stop working together on Hoodia; Camrivox partners with snow to add VoIP to Microsoft Outlook

Biotech Phytopharm fights back with good news, and a broker

Phytopharm’s losses widen; major programmes on track

Phytopharm gets FDA nod for Parkinson's disease drug trial

Briefs: CSR, Autonomy release new products: Phytopharm CEO, CFO leave; Dialight sees good progress

Phytopharm reports good headline results in Parkinson's disease studies

Phytopharm narrows losses, pleases market

Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com

Corporate profiles

 • ASM Scientific

Dr Niall Armes Managing Director

ASM Scientific Ltd is developing proprietary technology in the area of DNA amplifications and sequencing. Its novel approach to acquiring sequences from individual DNA strands, Direct Nucleic Acid Sequencing (DNAS), will permit the analysis of entire genomes in only days or hours. ASM Scientific is

[ASM Scientific's profile]

Top20 Index

Currently: 161